report
synthesi
new
seri
polycycl
amin
initi
design
ringrearrang
analog
amantadin
featur
pentacyclo
hexacyclo
octacyclo
ring
secondari
amin
effect
inhibit
proton
channel
function
moreov
possess
dual
activ
viru
carri
wildtyp
proton
channel
well
amantadineresist
viru
among
polycycl
amin
inhibit
influenza
proton
channel
function
sever
show
lowmicromolar
activ
test
strain
particular
strain
influenza
virus
mutant
select
resist
compound
possess
mutat
viral
hemagglutinin
markedli
increas
hemolysi
ph
data
suggest
virus
strain
particularli
sensit
subtl
increas
endosom
ph
caus
polycycl
amin
compound
adamantan
deriv
signific
interest
medicin
chemistri
lamoureux
artavia
liu
et
al
exampl
amantadin
amt
rimantadin
use
mani
year
antiinfluenza
viru
agent
jefferson
et
al
alv
et
al
adapalen
topic
retinoid
use
treat
skin
diseas
acn
et
al
vildagliptin
saxagliptin
recent
approv
type
diabet
villhauer
et
al
augeri
et
al
moreov
amt
dimethyl
deriv
memantin
nmda
receptor
antagonist
approv
treatment
parkinson
alzheim
diseas
respect
lipton
hubsher
et
al
fig
antiinfluenza
viru
activ
amt
rimantadin
base
inhibit
proton
channel
function
viral
protein
homotetramer
type
iii
integr
membran
protein
contain
small
ntermin
ectodomain
residu
helic
transmembran
domain
residu
form
pore
proton
channel
long
ctermin
cytoplasm
tail
residu
hong
degrado
pinto
lamb
wang
et
al
protein
differ
function
viral
life
cycl
includ
role
viru
assembl
bud
rossman
lamb
critic
role
viru
entri
situat
virion
enter
host
cell
endocytosi
name
proton
transport
requir
acidif
virion
interior
uncoat
viral
genom
cadi
et
al
hu
et
al
pinto
lamb
sharma
et
al
low
ph
insid
endosom
activ
proton
channel
also
induc
irrevers
conform
chang
viral
hemagglutinin
ha
lead
displac
hydrophob
fusion
peptid
direct
target
membran
fusion
viral
endosom
membran
cross
et
al
viral
genom
segment
releas
fusion
pore
cytoplasm
transport
nucleu
initi
rna
transcript
replic
recent
studi
cadi
et
al
cadi
et
al
rosenberg
casarotto
stouffer
et
al
identifi
bind
site
amt
rimantadin
within
channel
pore
structur
insight
also
provid
explan
intrins
inact
drug
influenza
b
viru
well
viral
resist
profil
current
circul
influenza
virus
amtresist
mutant
carri
substitut
transmembran
region
reduc
bind
amt
particular
bright
et
al
bright
et
al
wwwcdcgovflu
usa
amt
resist
increas
decemb
bright
et
al
center
diseas
control
prevent
recommend
use
amt
treatment
prophylaxi
influenza
smith
et
al
fior
et
al
reason
urgent
need
new
amt
analog
effect
common
amtresist
influenza
viru
mutant
signific
progress
field
recent
made
discoveri
polycycl
amin
deriv
activ
channel
carri
mutat
spiroadamantan
analogu
larger
size
amantadin
found
abl
block
channel
even
space
increas
substitut
wang
et
al
likewis
inhibit
channel
carri
mutat
increas
polar
caviti
accomplish
design
amantadineisoxazol
conjug
wang
et
al
whether
similar
mode
action
may
appli
imidazolelink
amantadin
analogu
report
equal
activ
wildtyp
remain
investig
zhang
et
al
past
year
group
synthes
sever
polycycl
amt
analog
contain
differ
scaffold
includ
ringcontract
camp
et
al
ringrearrang
duqu
et
al
torr
et
al
deriv
amt
fig
first
seri
ringrearrang
analog
amt
consist
amin
deriv
tertiari
amin
amidin
secondari
amin
evalu
inhibit
proton
channel
activ
use
conduct
assay
oocyt
duqu
et
al
secondari
amin
fig
display
similar
ic
valu
wt
amt
unfortun
inact
amtresist
mutant
form
duqu
et
al
also
found
tertiari
amin
diethyl
deriv
minim
activ
wt
protein
conduct
assay
strikingli
found
display
low
micromolar
activ
influenza
strain
cell
cultur
sinc
strain
carri
two
amt
resist
mutat
protein
mode
action
unrel
inhibit
appli
compound
intrigu
subtypedepend
activ
virus
particular
strain
also
observ
recent
seri
deriv
gener
structur
torr
et
al
fig
present
report
first
describ
synthesi
novel
seri
pentacycl
hexacycl
octacycl
alkyl
amin
amidin
guanidin
deriv
amin
intrigu
find
alik
sever
polycycl
amin
compound
activ
virus
perform
broad
antiinfluenza
viru
test
select
character
resist
virus
result
indic
polycycl
amin
interfer
hamedi
fusion
caus
subtl
increas
endosom
ph
virus
particularli
sensit
ph
effect
melt
point
determin
open
capillari
tube
mfb
gallenkamp
melt
point
apparatu
mhz
h
nmr
mhz
c
nmr
spectra
record
varian
mercuri
spectromet
mhz
h
nmr
mhz
c
nmr
spectra
perform
varian
inova
equip
except
otherwis
state
h
nmr
mhz
c
nmr
mhz
spectra
carri
cd
od
solut
chemic
shift
report
ppm
scale
rel
intern
tetramethylsilan
coupl
constant
report
hertz
hz
assign
given
nmr
spectra
new
compound
base
dept
cosi
h
h
standard
procedur
cosi
h
c
ghsqc
ghmbc
sequenc
experi
select
compound
ir
spectra
run
perkinelm
spectrum
rx
spectrophotomet
alway
kbr
absorpt
valu
express
wavenumb
cm
signific
absorpt
band
given
ms
gcm
analys
sampl
introduc
directli
ga
chromatograph
respect
use
hewlettpackard
mass
spectromet
gcm
analys
column
dimethylpolysiloxan
condit
psi
initi
temperatur
min
heat
rang
till
isotherm
use
electron
impact
ev
chemic
ioniz
ch
techniqu
use
high
resolut
mass
spectra
carri
micromass
autospec
lcmsd
tof
agil
technolog
spectromet
column
chromatographi
perform
silica
gel
acc
mesh
sd
ref
oocyt
plasma
membran
mutant
form
gener
quikchang
sitedirect
mutagenesi
kit
agil
technolog
synthesi
mrna
microinject
oocyt
carri
describ
et
al
h
mrna
inject
macroscop
record
membran
current
perform
balannik
et
al
inward
current
reach
maximum
variou
concentr
test
compound
ad
ph
compound
appli
min
residu
membran
current
compar
membran
current
compound
applic
data
analyz
pclamp
softwar
axon
instrument
sunnyval
ca
antivir
activ
compound
determin
establish
cpe
reduct
assay
use
divers
set
dna
rna
virus
indic
includ
three
sub
type
influenza
viru
apuerto
ahong
bhong
naesen
et
al
vanderlinden
et
al
compound
addit
test
influenza
viru
strain
pandem
detail
origin
virus
antivir
test
procedur
found
elsewher
vanderlinden
et
al
briefli
madindarbi
canin
kidney
cell
seed
plate
expos
influenza
viru
multipl
infect
ccid
cell
cultur
infect
dose
per
well
togeth
test
compound
three
day
incub
microscopi
perform
score
virusinduc
cytopath
effect
cpe
well
compound
cytotox
data
confirm
colorimetr
formazanbas
mt
cell
viabil
assay
antivir
activ
express
ec
valu
compound
concentr
produc
inhibit
virusinduc
cpe
determin
microscopi
mt
assay
compound
cytotox
express
minimum
inhibitori
concentr
mcc
ie
concentr
produc
minim
chang
cell
morpholog
cc
valu
ie
concentr
caus
reduct
cell
viabil
mt
assay
determin
effect
compound
viru
yield
mdck
cell
incub
influenza
viru
strain
compound
supernat
collect
day
pi
serial
dilut
sampl
ad
mdck
cell
seed
plate
day
incub
viral
cpe
score
microscopi
viru
titer
calcul
ccid
method
reed
muench
influenza
viru
strain
pass
mdck
cell
presenc
absenc
test
compound
passag
viruscontain
supernat
collect
well
show
clear
cpe
day
post
infect
viru
appli
fresh
mdck
cell
addit
compound
gradual
increas
concentr
lm
seven
passag
harvest
viru
plaquepurifi
mdck
cell
condit
compound
three
individu
clone
collect
expand
mdck
cell
viru
clone
subject
full
ha
gene
sequenc
use
utrdirect
outer
primer
hoffmann
et
al
well
customsynthes
inner
primer
antivir
sensit
mutant
virus
determin
cpe
reduct
assay
describ
publish
procedur
use
determin
ph
erythrocyt
hemolysi
vanderlinden
et
al
briefli
allanto
influenza
viru
stock
chicken
red
blood
cell
rbc
incub
min
centrifug
rbc
pellet
resuspend
pb
ph
lower
addit
n
acet
acid
sampl
incub
min
reaction
neutral
naoh
intact
rbc
remov
centrifug
supernat
transfer
plate
optic
densiti
measur
nm
background
valu
deriv
mockinfect
sampl
undergo
ident
treatment
ph
erythrocyt
hemolysi
express
ph
hemolysi
occur
rel
valu
ph
start
primari
amin
previous
perform
synthesi
tertiari
amin
acetamidin
duqu
et
al
explor
effect
alkyl
biolog
activ
treat
formaldehyd
nacnbh
obtain
tertiari
amin
yield
treatment
nacnbh
led
yield
fig
similarli
primari
amin
reduct
alkyl
benzaldehyd
formaldehyd
acetaldehyd
nacnbh
led
amin
respect
high
yield
alkyl
led
piperidin
deriv
yield
reduct
methyl
secondari
amin
formaldehyd
nacnbh
led
yield
tertiari
amin
catalyt
hydrogen
quantit
furnish
secondari
amin
previous
synthes
treatment
ethyl
chloroformi
follow
reduct
lialh
overal
yield
order
studi
whether
basic
nitrogen
atom
may
affect
antivir
activ
synthes
acetamidin
reaction
amin
methyl
acetimid
guanidin
reaction
amin
final
start
known
acid
camp
et
al
prepar
rimantadin
analog
sequenc
involv
format
keton
convers
oxim
lialh
reduct
fig
similar
way
start
known
pyrrolidin
deriv
synthes
methyl
deriv
respect
reduct
alkyl
formaldehyd
nacnbh
hydrogen
dien
led
fulli
satur
deriv
also
correspond
acetamidin
guanidin
deriv
respect
synthes
high
yield
fig
new
compound
except
fulli
character
hydrochlorid
spectroscop
data
element
analys
see
supplementari
data
compound
fulli
character
tartrat
spectroscop
data
high
resolut
mass
spectrum
hrm
select
compound
evalu
inhibitori
activ
toward
protein
express
xenopu
oocyt
use
twoelectrod
voltag
clamp
tev
techniqu
et
al
balannik
et
al
compound
initi
test
lm
inhibit
wt
channel
activ
subsequ
test
doserespons
experi
determin
inhibitori
concentr
ic
result
given
tabl
amt
inhibit
wt
channel
ic
lm
similar
valu
obtain
rimantadin
ic
lm
previous
report
secondari
amin
inhibit
wt
channel
ic
valu
similar
amt
ic
lm
lm
respect
duqu
et
al
alik
amt
rimantadin
compound
inact
mutant
form
data
shown
also
determin
inhibitori
activ
sever
novel
compound
ie
pyrrolidin
deriv
unfortun
neither
significantli
inhibit
wt
channel
amt
analog
synthes
subject
antivir
evalu
wide
rang
dna
rna
virus
use
cpe
reduct
assay
relev
cell
line
none
compound
display
activ
envelop
dna
virus
herp
simplex
viru
type
type
vaccinia
viru
envelop
rna
virus
felin
coronaviru
viru
respiratori
syncyti
viru
vesicular
stomat
viru
sindbi
viru
punta
toro
viru
nonenvelop
rna
virus
coxsackieviru
data
shown
basic
cpe
reduct
assay
influenza
viru
perform
mdck
cell
cultur
three
viru
strain
use
strain
viru
two
amtresist
mutat
protein
strain
wt
protein
strain
antivir
data
obtain
microscop
score
virusinduc
cpe
confirm
colorimetr
mt
cell
viabil
assay
data
shown
parallel
compound
appli
uninfect
mdck
cell
estim
cytotox
microscopi
mt
cell
viabil
assay
shown
tabl
cell
cultur
activ
viru
ic
valu
wt
proton
channel
function
tabl
howev
case
biscyclopropan
deriv
octacyclo
compound
latter
compound
quit
pronounc
cytotox
mdck
cell
threeday
cpe
reduct
assay
mcc
lm
cc
lm
may
mask
potenti
inhibitori
effect
toward
viru
strike
contrast
overal
lack
activ
viru
sever
polycycl
amin
display
low
micromolar
activ
influenza
viru
mani
activ
compound
produc
cytotox
lm
highest
concentr
test
yield
favor
select
index
defin
ratio
cytotox
antivir
concentr
viru
compound
show
highest
potenc
ec
lm
less
two
tertiari
amin
dien
biscyclopropan
secondari
amin
guanidin
anticip
compound
prove
inact
influenza
b
viru
data
shown
known
insensit
amt
rimantadin
analysi
structureact
relationship
antia
data
yield
follow
insight
pentacycl
compound
deriv
primari
amin
ic
lm
display
activ
viru
diethylderiv
potent
select
one
ec
lm
select
index
contrast
among
deriv
primari
amin
ec
lm
guanidin
ec
lm
potent
parent
compound
compound
reason
select
index
activ
reduc
substitut
amantadinelik
structur
ec
lm
rimantadinelik
structur
ec
lm
note
go
primari
amin
basic
acetamidin
complet
loss
antivir
activ
observ
methyl
primari
amin
ec
lm
ec
lm
led
less
potent
compound
lm
lm
lm
pyrrolidin
deriv
correspond
methyl
compound
respect
display
similar
antivir
activ
ec
valu
low
micromolar
rang
pyrrolidin
deriv
ec
lm
methyl
deriv
consider
activ
ec
lm
impact
introduc
strongli
basic
guanidin
group
less
clear
amin
less
potent
correspond
guanidin
respect
complet
loss
antivir
activ
observ
go
amin
correspond
guanidin
respect
sever
compound
activ
strain
strain
evalu
strain
strain
carri
wt
protein
select
compound
ie
also
inact
avictoria
strain
ec
lm
highest
concentr
test
data
shown
data
argu
possibl
inact
compound
viru
may
specif
strain
two
potent
compound
tertiari
amin
endow
submicromolar
activ
strain
ec
lm
respect
secondari
amin
ec
lm
well
three
deriv
recent
synthes
fig
character
gene
sequenc
detect
amtresist
mutat
determin
hemolysi
ph
tabl
latter
done
context
find
resist
polycycl
amin
associ
mutat
ha
protein
lead
increas
hemolysi
ph
see
shown
tabl
three
polycycl
compound
well
three
deriv
ident
spectrum
antiinfluenza
viru
activ
show
micromolar
activ
four
strain
total
inact
three
strain
final
strong
inhibitori
effect
strain
confirm
viru
yield
assay
mdck
cell
tabl
three
polycycl
amin
compound
evalu
assay
produc
strong
reduct
infecti
viru
titer
ec
valu
ie
concentr
produc
reduct
viru
titer
lm
lm
lm
amantadin
rimantadin
much
less
potent
sinc
ec
valu
lm
respect
strict
activ
structur
divers
polycycl
amin
virus
whether
contain
wt
amtresist
protein
point
viral
hemagglutinin
like
antivir
target
known
sinc
mani
year
inhibit
amantadin
occur
lower
micromolar
compound
concentr
higher
concentr
lm
amantadin
increas
endosom
ph
therebi
interf
low
phinduc
hamedi
membran
fusion
daniel
et
al
explain
virus
select
amantadin
cell
cultur
regularli
contain
mutat
ha
increas
fusion
ph
viru
mutant
adopt
fusogen
conform
less
acid
ph
thu
escap
phincreas
effect
amantadin
studi
serial
pass
influenza
viru
presenc
secondari
hexacycl
amin
tertiari
amin
chosen
superior
select
make
possibl
appli
compound
concentr
high
lm
two
compound
repres
structur
seri
secondari
amin
tertiari
amin
control
condit
viru
pass
absenc
test
compound
includ
identifi
ha
mutat
appear
viru
produc
egg
adapt
cell
cultur
summar
tabl
five
residu
chang
use
number
gamblin
et
al
detect
polypeptid
part
ha
protein
sequenc
analysi
parent
allanto
stock
show
stage
viru
still
homogen
sinc
doubl
peak
observ
wide
survey
publish
sequenc
ha
bao
et
al
http
wwwncbinlmnihgovgenomesflu
fluhtml
demonstr
two
five
chang
ie
ha
ha
observ
variat
report
suggest
chang
natur
occur
without
select
pressur
viru
pass
absenc
compound
ha
substitut
becam
appar
two
passag
mutant
one
remain
eight
passag
indic
result
cell
cultur
adapt
viru
two
remain
chang
clearli
select
polycycl
amin
ha
present
passag
select
compound
ha
alreadi
appar
two
passag
viru
select
also
contain
ha
ha
chang
appear
earli
relev
clear
sinc
explain
may
well
polymorph
chang
sequenc
data
strongli
argu
role
ha
protein
antivir
mode
action
like
polycycl
amin
studi
parallel
seen
ha
chang
obtain
amt
result
increas
fusion
ph
thu
render
viru
resist
phincreas
effect
amt
daniel
et
al
therefor
determin
hemolysi
ph
defin
ph
hemolysi
occur
viru
attach
erythrocyt
expos
differ
acid
buffer
vanderlinden
et
al
hemolysi
ph
parent
allanto
viru
quit
low
tabl
valu
increas
cell
cultureadapt
viru
contain
ha
chang
mutant
virus
obtain
consider
higher
hemolysi
ph
respect
indic
acquisit
less
stabl
ha
abl
fuse
higher
ph
confer
resist
polycycl
amin
antivir
evalu
passag
parent
allanto
stock
test
parallel
demonstr
fusion
mutant
obtain
fulli
resist
polycycl
amin
crossresist
amt
rimantadin
wherea
sensit
ribavirin
allanto
viru
tabl
viru
obtain
absenc
compound
intermedi
hemolysi
ph
less
sensit
four
amt
deriv
factor
increas
antivir
ec
compar
parent
allanto
viru
compound
compound
amt
rimantadin
thu
correl
seen
viral
hemolysi
ph
antivir
sensit
four
amin
endocyt
uptak
influenza
viru
host
cell
viral
genom
segment
must
releas
cytoplasm
transport
nucleu
initi
rna
transcript
replic
cross
et
al
endosom
escap
viru
critic
depend
activ
two
viral
protein
activ
low
endosom
ph
proton
channel
requir
uncoat
viral
ribonucleoprotein
ha
protein
upon
acidif
adopt
fusogen
conform
caus
fusion
endosom
viral
membran
format
fusion
pore
cross
et
al
therefor
dualli
act
polycycl
amin
combin
blockad
channel
inhibitori
effect
ha
refold
appear
highli
attract
dual
approach
could
also
least
theori
increas
barrier
select
adamantan
resist
scholtissek
et
al
optim
adamantan
deriv
might
abl
exert
dual
pharmacolog
effect
provid
nd
nd
nd
amantadin
rimantadin
oseltamivir
carboxyl
nd
zanamivir
nd
ribavirin
nd
determin
mcc
minimum
cytotox
concentr
compound
concentr
produc
minim
alter
cell
morpholog
b
pandem
viru
strain
c
viru
strain
entir
code
region
sequenc
residu
associ
amt
resist
ie
locat
residu
mention
viru
strain
hemolysi
ph
determin
defin
ph
hemolysi
occur
see
vanderlinden
et
al
procedur
e
ec
repres
compound
concentr
produc
inhibit
viru
replic
determin
microscop
score
cpe
ha
inhibit
occur
similar
relev
compound
concentr
comparison
block
effect
amt
achiev
micromolar
concentr
wherea
increas
effect
endosom
ph
requir
much
higher
concentr
ie
rang
lm
high
amt
concentr
achiev
vivo
standard
amt
drug
regimen
sinc
report
plasma
concentr
valu
amt
rang
lm
hayden
et
al
henc
potenti
exploit
effect
adamantan
deriv
ha
refold
novel
analogu
potent
activ
would
requir
past
year
group
synthes
differ
seri
polycycl
amin
first
aim
improv
inhibitori
effect
toward
andor
achiev
activ
amtresist
proton
channel
camp
et
al
duqu
et
al
torr
et
al
upon
evalu
compound
influenza
virusinfect
cell
notic
sever
display
micromolar
activ
viru
viru
carri
two
characterist
amt
resist
mutat
protein
inact
viru
contain
wt
present
report
particular
subtyp
depend
investig
detail
use
differ
seri
polycycl
amin
includ
newli
synthes
seri
hexacyclo
octacyclo
compound
broad
panel
virus
cpe
reduct
assay
low
micromolar
activ
ec
lm
viru
observ
sever
compound
notic
pyrrolidin
deriv
primari
amin
secondari
amin
tertiari
amin
guanidin
potent
deriv
dien
ec
valu
lm
select
index
anoth
intrigu
compound
hexacyclodien
activ
strain
moreov
inhibit
wt
channel
function
similar
ic
valu
amantadin
compound
may
repres
lead
dualli
act
polycycl
amin
increas
antivir
potenc
synthesi
compound
deriv
consid
hypothes
potent
activ
polycycl
amin
amtresist
viru
like
result
interfer
hamedi
fusion
alik
seen
high
concentr
amt
viru
mutant
obtain
serial
passag
presenc
secondari
amin
tertiari
amin
inde
contain
mutat
ha
protein
consider
increas
ph
hemolysi
mean
mutant
adopt
fusogen
conform
higher
ph
fig
five
residu
subject
mutat
passag
virus
locat
publish
crystal
structur
ha
gamblin
et
al
three
chang
ha
locat
globular
head
ha
ha
locat
ha
stem
near
fusion
peptid
seem
polymorph
andor
relat
cell
cultur
adapt
lin
et
al
henc
consid
irrelev
context
polycycl
amin
ha
residu
chang
select
previous
identifi
daniel
et
al
amtresist
avian
viru
weybridg
strain
manifest
increas
hemolysi
ph
ph
unit
ha
mutat
also
report
plotch
et
al
select
viru
resist
small
molecul
fusion
inhibitor
start
amtresist
viru
increas
fusion
ph
ha
mutant
viru
unexpect
sinc
residu
lie
hydrophob
fusion
peptid
ha
report
introduct
less
hydrophob
residu
fusion
peptid
result
increas
fusion
ph
cross
et
al
side
chain
ha
locat
heart
trimer
ha
stem
make
sever
hydrophob
contact
among
surround
residu
replac
residu
smaller
leucin
probabl
decreas
hydrophob
interact
surround
residu
may
promot
easier
releas
fusion
peptid
bind
posit
thu
explain
increas
fusion
ph
regard
ha
substitut
select
compound
impact
residu
chang
less
obviou
neutral
ph
structur
ha
protein
fig
residu
lie
adjac
number
gamblin
et
al
report
directli
interact
fusion
peptid
via
format
two
hydrogen
bond
ie
ha
ha
thoenn
et
al
correspond
residu
ha
number
requir
water
molecul
interact
fusion
peptid
contrast
tyrosin
proton
fusion
ph
critic
role
residu
trigger
membran
fusion
explain
conserv
includ
ha
wherea
includ
ha
contain
correspond
posit
thoenn
et
al
import
ha
region
consist
observ
ha
substitut
drastic
reduc
stabil
ha
result
hemolysi
ph
high
one
explan
may
hydroxylcontain
thr
residu
posit
may
disturb
hydrogen
bond
fusion
peptid
fact
polycycl
amin
select
escap
mutant
increas
fusion
ph
indic
compound
interfer
hamedi
fusion
process
one
potenti
mode
action
ie
direct
bind
polycycl
amin
compound
prefusogen
ha
protein
therebi
prevent
refold
low
ph
exclud
hemolysi
inhibit
experi
viru
previous
use
hemolysi
assay
identifi
small
molecul
fusion
inhibitor
virus
act
bind
hydrophob
pocket
prefusogen
ha
protein
vanderlinden
et
al
none
three
polycycl
amin
test
inhibit
low
phinduc
hemolysi
lm
data
shown
addit
compound
produc
effect
hemagglutin
inhibit
assay
data
argu
direct
bind
interact
polycycl
amin
ha
region
involv
receptor
bind
membran
fusion
thu
analog
amt
probabl
polycycl
amin
act
caus
slight
increas
endosom
ph
wherea
ph
effect
amt
seen
lm
concentr
compound
act
lower
concentr
mode
action
explain
within
panel
strain
test
correl
seen
antivir
ec
valu
viral
hemolysi
ph
tabl
also
markedli
increas
hemolysi
ph
mutant
resist
polycycl
amin
mean
mutant
abl
fuse
condit
higher
endosom
ph
induc
amin
compound
tri
provid
direct
evid
effect
endosom
ph
perform
acridin
orang
assay
confoc
microscopi
visual
acidotrop
dye
becom
proton
sequest
insid
acid
endosom
give
shift
green
red
fluoresc
lysosom
red
fluoresc
complet
inhibit
vatpas
inhibitor
bafilomycin
wherea
condit
receiv
chloroquin
show
decreas
lysosom
ph
shift
yellow
fluoresc
data
shown
similar
report
vanderlinden
et
al
contrast
neither
polycycl
amin
test
ie
amantadin
lm
compound
lm
chang
acridin
orang
stain
pattern
compar
untreat
cell
data
shown
thu
appear
effect
amin
compound
endosom
ph
subtl
detect
acridin
orang
assay
agreement
previou
data
report
amantadin
natal
mccullough
pettersen
et
al
one
monom
ha
trimer
color
blue
ha
pink
ha
two
monom
light
grey
fusion
peptid
residu
nterminu
ha
cyan
side
chain
relev
residu
label
follow
ha
green
ha
yellow
ha
orang
ha
red
ha
blue
residu
mark
purpl
specif
ha
directli
interact
fusion
peptid
via
format
two
hydrogen
bond
thoenn
et
al
except
ha
locat
globular
head
ha
mark
residu
lie
close
within
fusion
peptid
chang
posit
observ
viru
passag
cell
cultur
presenc
compound
absenc
compound
associ
increas
ph
hemolysi
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
strike
observ
antivir
sensit
polycycl
amin
mere
determin
viral
fusion
ph
sinc
ha
subtyp
ie
act
real
discrimin
factor
convinc
evid
come
result
strain
display
opposit
sensit
polycycl
amin
despit
similarli
low
hemolysi
ph
thu
appear
ha
featur
make
suscept
slight
increas
endosom
ph
parallel
may
seen
report
viru
particularli
sensit
inactiv
low
ph
kort
et
al
demonstr
fusion
activ
viru
rapidli
lost
viru
preincub
ph
viru
inactiv
requir
longer
preincub
time
lower
ph
author
show
ph
ha
display
higher
exposur
hydrophob
residu
compar
ha
relev
initi
membran
fusion
fast
inactiv
ha
low
ph
propos
relat
two
characterist
glu
residu
lie
close
globular
head
ha
protein
caus
electrostat
repuls
weaker
trimer
stabil
rachakonda
et
al
altern
explan
antivir
activ
polycycl
amin
may
viru
strain
possess
second
cluster
basic
particularli
histidin
residu
adjac
vestigi
esteras
domain
second
basic
patch
also
found
pandem
ha
zhang
et
al
ha
suggest
second
basic
patch
creat
extra
electrostat
repuls
ha
expos
acid
ph
sinc
second
cluster
basic
residu
also
present
ha
avian
influenza
virus
steven
et
al
would
relev
investig
whether
virus
sensit
polycycl
amin
unfortun
due
biosafeti
constraint
experi
could
perform
laboratori
regard
pandem
viru
viru
prove
inhibit
polycycl
amin
although
antivir
concentr
higher
viru
compar
note
consist
find
latter
strain
lowest
hemolysi
ph
strain
examin
knowledg
first
provid
experiment
evid
suggest
compar
influenza
virus
virus
particular
sensit
subtl
alter
endosom
ph
caus
polycycl
amin
compound
